title: Who benefits from tricyclic antidepressants: a survey.
abstract: To determine what patients are likely to benefit from treatment with a tricyclic antidepressant, the authors surveyed American researchers, teachers of psychiatry, general psychiatric practitioners, and foreign researchers. Areas of agreement were appreciable and can serve as an index of accepted community practice and as guidelines for teaching. Responses indicated that patients most likely to benefit from a tricyclic antidepressant are those with primary depression; early morning awakening; motor retardation; loss of appetite; weight loss; prior positive response to a tricyclic antidepressant; loss of interest in work or hobbies; sad, blue, or depressed feelings; improved mood in evening; and loss of interest in sex. Amitriptyline was preferred for agitated depressions, and imipramine was preferred for retarded depressions.
authors: Department of Psychiatry, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.
authors: S C
authors: SC
authors: Goldberg
authors: D H
authors: DH
authors: Tilley
authors: R O
authors: RO
authors: Friedel
authors: R M
authors: RM
authors: Hamer
authors: T A
authors: TA
authors: Ban
authors: C
authors: C
authors: Brockett
authors: P
authors: P
authors: Bale
authors: V
authors: V
authors: Stephens
mesh_terms: D000639:Amitriptyline / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D011570:Psychiatry; D012189:Retrospective Studies
chemical_list: D000929:Antidepressive Agents, Tricyclic; D000639:Amitriptyline; D007099:Imipramine